Metagenomi (NASDAQ:MGX) Releases Earnings Results, Misses Estimates By $0.01 EPS

Metagenomi (NASDAQ:MGX) posted its earnings results on Monday. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01), FiscalAI reports. Metagenomi had a negative net margin of 348.54% and a negative return on equity of 47.14%. The business had revenue of $1.25 million during the quarter, compared to analysts’ expectations of $5.90 million.

Metagenomi Trading Down 3.9%

Shares of MGX stock traded down $0.06 on Monday, reaching $1.36. The company’s stock had a trading volume of 181,161 shares, compared to its average volume of 230,506. The stock’s fifty day simple moving average is $1.45 and its 200-day simple moving average is $1.69. Metagenomi has a 1 year low of $1.25 and a 1 year high of $3.95. The company has a market capitalization of $51.02 million, a price-to-earnings ratio of -0.57 and a beta of 0.63.

Analyst Ratings Changes

MGX has been the subject of a number of recent research reports. Wall Street Zen lowered shares of Metagenomi from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Weiss Ratings raised shares of Metagenomi from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $10.00.

Institutional Trading of Metagenomi

A number of institutional investors have recently bought and sold shares of MGX. Renaissance Technologies LLC lifted its position in Metagenomi by 276.3% in the fourth quarter. Renaissance Technologies LLC now owns 628,400 shares of the company’s stock worth $1,018,000 after buying an additional 461,400 shares during the last quarter. Jane Street Group LLC lifted its position in Metagenomi by 341.6% in the fourth quarter. Jane Street Group LLC now owns 433,859 shares of the company’s stock worth $703,000 after buying an additional 335,604 shares during the last quarter. Norges Bank bought a new stake in Metagenomi in the second quarter worth $373,000. Bridgeway Capital Management LLC lifted its position in Metagenomi by 102.1% in the fourth quarter. Bridgeway Capital Management LLC now owns 395,800 shares of the company’s stock worth $641,000 after buying an additional 200,000 shares during the last quarter. Finally, Two Sigma Investments LP lifted its position in Metagenomi by 1,394.4% in the third quarter. Two Sigma Investments LP now owns 207,528 shares of the company’s stock worth $492,000 after buying an additional 193,641 shares during the last quarter.

Metagenomi Company Profile

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.